News : University of Pittsburgh Cancer Institute

PITTSBURGH, Aug. 19 – Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine have been awarded an $800,000 federal grant to develop agents to inhibit a cellular signaling protein that plays a key role in triggering and supporting the growth of many cancers, including cancers of the head and...

CHICAGO, June 9 – Shannon Puhalla, M.D., assistant professor of medicine, University of Pittsburgh School of Medicine, and breast oncologist with the Magee-Womens Cancer Program of UPMC Cancer Centers, has received a 2010 Career Development Award from the American Society of Clinical Oncology (ASCO).
The award provides $200,000 over three years for physicians in their first to third year of practice to...

CHICAGO, June 7 – An educational session exploring the complexities of oral chemotherapy, a development in cancer treatment that has occurred over the last decade, will be chaired today by Merrill Egorin, M.D., professor of medicine and pharmacology at the University of Pittsburgh Cancer Institute (UPCI), at...
Traditionally, cancer patients have received chemotherapy intravenously while under the care of...

CHICAGO, June 5 – Researchers from the University of Pittsburgh Cancer Institute (UPCI) Melanoma Program, led by John M. Kirkwood, M.D., will present findings from seven studies at the American Society of Clinical Oncology annual meeting, June 4 to 8, at McCormick Place in...
Phase II Trial of Dasatinib in Patients with Advanced Melanoma

Sponsored by ECOG

Pre-clinical studies show that a specific gene...

CHICAGO, June 5 – Researchers from the University of Pittsburgh Cancer Institute (UPCI) Melanoma Program, led by John M. Kirkwood, M.D., will present findings from seven studies at the American Society of Clinical Oncology annual meeting, June 4 to 8, at McCormick Place in...
Phase II Trial of Tremelimunab Combined with High-Dose Interferon alpha-2b for Metastatic Melanomas

Sponsored by UPCI

Previous...

CHICAGO, June 5 – Researchers from the University of Pittsburgh Cancer Institute (UPCI) Melanoma Program, led by John M. Kirkwood, M.D., will present findings from seven studies at the American Society of Clinical Oncology annual...
Highlights of their findings include:

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Metastatic Melanoma

Sponsored by the Southwest Oncology...

CHICAGO, June 5 – The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation today at the 46th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
“With each new study, we learn something important about the treatment of melanoma,”...

CHICAGO, June 5 – The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation today at the 46th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
“With each new study, we learn something important about the treatment of melanoma,”...

PITTSBURGH, June 1 – Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.
The findings are published in Science Signaling and provide new insights into mechanisms of how the body fixes...